Decapeptyl-CR 3

DRUG2 trials

Sponsors

UZ Leuven, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Conditions

Oligorecurrent hormone-sensitive prostate cancer patientslow-volume metastatic castration-sensitive prostate cancer

Phase 3

Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.

RecruitingCTIS2022-502373-42-00

UZ LeuvenOligorecurrent hormone-sensitive prostate cancer patients

Start: 2022-04-25Target: 873Updated: 2025-03-31

Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial

RecruitingCTIS2023-506698-36-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)low-volume metastatic castration-sensitive prostate cancer

Start: 2024-02-02Target: 400Updated: 2025-12-03